放射性药物产品和服务提供商PharmaLogic完成对Agilera Pharma多数股权的收购-动脉网

PharmaLogic Completes Acquisition of Majority Stake in Agilera Pharma AS

CISION 等信源发布 2025-06-23 20:00



可切换为仅中文







BOCA RATON, Fla.

博卡拉顿，佛罗里达州

and

和

OSLO, Norway

挪威奥斯陆

，

June 23, 2025

2025年6月23日

/PRNewswire/ --

PharmaLogic Holdings Corp

药明康德控股公司

. ('PharmaLogic' or 'the Company'), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the completion of its

（'PharmaLogic' 或 '公司'），一家专注于放射性药物的领先合同开发和制造组织 (CDMO)，今日宣布已完成其

previously announced

之前宣布的

acquisition of a majority stake in

收购多数股权

Agilera Pharma AS

阿吉莱拉制药公司

('Agilera') from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company's strategy to create the first fully-integrated, global CDMO platform specializing in radiopharmaceutical therapeutics.

（“阿吉莱拉”）来自挪威能源技术研究所 (IFE)，标志着该公司在创建首个专注于放射性药物治疗的全球一体化 CDMO 平台的战略上迈出了重要一步。

The acquisition significantly enhances PharmaLogic's capabilities across the development, manufacturing, and global distribution of commercial and clinical therapeutic radiopharmaceuticals, broadening the company's geographic reach and operational scale.

此次收购显著增强了PharmaLogic在商业和临床治疗放射性药物的开发、制造和全球分销方面的能力，扩大了公司的地理覆盖范围和运营规模。

'The addition of Agilera's capabilities to PharmaLogic marks a key milestone in our expansion strategy into radiopharmaceutical therapeutics,' said

“将Agilera的能力引入PharmaLogic标志着我们向放射性药物治疗领域扩展战略的关键里程碑，”

Etienne Montagut

艾蒂安·蒙塔古

, President and CEO of PharmaLogic. 'Their proven expertise in the development and manufacturing of commercial radiopharmaceutical therapies, evidenced by successful distribution to over 30 countries, significantly enhances our end-to-end solutions. We warmly welcome the talented Agilera team and look forward to shaping the future of radiopharmaceuticals together.'.

，PharmaLogic的总裁兼首席执行官。“他们在商业放射性药物疗法的开发和制造方面有着公认的专长，并成功分销至超过30个国家，这极大地增强了我们的端到端解决方案。我们热烈欢迎才华横溢的Agilera团队，并期待共同塑造放射性药物的未来。”

Advisors

顾问

Solomon Partners Securities, LLC served as financial advisor on the acquisition.

所罗门合伙证券有限公司担任了此次收购的财务顾问。

About PharmaLogic Holdings Corp.

关于PharmaLogic控股公司

PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S.,

PharmaLogic 是一家全球领先的合同开发和制造组织 (CDMO)，专注于诊断和治疗用放射性药物。凭借数十年的行业经验以及在美国超过 45 个设施的强大网络，

Puerto Rico

波多黎各

，

Canada

加拿大

, and

，以及

Norway

挪威

, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards.

，PharmaLogic 提供涵盖开发、制造和分销临床及商业化阶段放射性药物产品的全面解决方案，均符合最高质量与监管标准。

Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and neurology. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries across the globe..

我们快速发展的诊断业务利用先进技术，增强患者在肿瘤学、心脏病学和神经学领域获得新型诊断的机会。在治疗领域，PharmaLogic 是全球唯一符合 cGMP 标准的 CDMO，目前生产和分销商业放射性药物治疗产品，覆盖全球 30 多个国家。

PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn..

PharmaLogic 致力于通过与行业创新者建立战略开发合作伙伴关系，推动全球患者获得放射性药物的机会，推进行业未来的发展，并在产品生命周期内为我们的合作伙伴提供支持。欲了解更多信息，请访问 radiopharmacy.com 并在 LinkedIn 上关注我们。

About IFE

关于IFE

IFE was established in 1948 to conduct research on nuclear energy and has built and operated four experimental reactors at Kjeller and in Halden. IFE was a frontrunner and started with radiopharmaceutical activities as early as 1952 at the research reactor JEEP I at Kjeller. In the 1960s, IFE offered 28 individual radioactive isotopes for use in diagnostics and treatment and was particularly known for its labeling technology.

IFE成立于1948年，致力于核能研究，并在凯勒和哈尔登建造和运行了四个实验反应堆。IFE是先锋者，早在1952年就在凯勒的JEEP I研究反应堆开始了放射性药物活动。在20世纪60年代，IFE提供了28种单独的放射性同位素用于诊断和治疗，尤其以其标记技术而闻名。

During the 1980s and 90s, IFE exported its production technology to several countries. IFE was a key player in the introduction of PET technology in Norway, which has been of great importance for the diagnosis of cancer. Over the past 10 years, IFE has developed radiopharmaceutical activities to become a successful contract development and manufacturing organization with a global footprint.

在 20 世纪 80 年代和 90 年代，IFE 向多个国家出口了其生产技术。IFE 是将 PET 技术引入挪威的关键参与者，该技术对癌症的诊断具有重要意义。在过去的十年中，IFE 发展了放射性药物业务，成为一家成功的合同开发和制造组织，足迹遍布全球。

In 2023, IFE spun off the radiopharmaceutical business into a newly created subsidiary, Agilera Pharma AS..

2023年，IFE将放射性药物业务剥离到新成立的子公司Agilera Pharma AS。

About Agilera Pharma AS

关于Agilera Pharma AS

Agilera Pharma AS was established as a subsidiary of IFE in 2023 with 140 employees as part of their organization. Agilera has three business areas:

Agilera Pharma AS 于2023年作为IFE的子公司成立，拥有140名员工作为其组织的一部分。Agilera有三个业务领域：

CDMO

合同开发和制造组织

: Development partner for innovative radiopharmaceuticals from early phase to clinical production, tailored to customer needs.

：从早期阶段到临床生产的创新放射性药物的开发合作伙伴，根据客户需求量身定制。

CMO

首席营销官

: production and distribution at scale in over 30 countries a commercial radiopharmaceutical therapy for a large pharmaceutical company. Permits from the Norwegian Medicines Agency and GMP certified.

：在超过30个国家大规模生产和分销一种用于大型制药公司的商业放射性药物治疗。获得挪威药品管理局许可，并通过GMP认证。

Wholesaler and distribution

批发商和分销

: Agilera is the national wholesaler of radiopharmaceuticals in Norway. Agilera has a central pharmacy function for radiopharmaceuticals and a logistics centre that distributes radiopharmaceuticals throughout Norway and globally.

Agilera是挪威全国的放射性药物批发商。Agilera拥有一个负责放射性药物的中央药房职能和一个物流中心，该中心负责将放射性药物分发至挪威全国及全球。

SOURCE PharmaLogic Holdings Corp

来源：PharmaLogic控股公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers